Significance and impact of bisphosphonate-induced acute phase responses
- 1 December 2007
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 13 (4), 223-229
- https://doi.org/10.1177/1078155207080806
Abstract
Background: Bisphosphonates are synthetic analogs of inorganic pyrophosphates with high avidity for bone, where they bind to hydroxyapatite crystals. Bisphosphonates are effective in decreasing bone resorption, the incidence of skeletal-related events, and pain from bone metastases. These agents have recently become incorporated into the treatment regimen of patients with osteolytic and osteoblastic metastatic bone disease. Although relatively well tolerated, the initial dose(s) of intravenous aminobisphosphonates can be associated with an acute phase response, a nonspecific physiologic reaction associated with increased levels of inflammatory cytokines, fever, and flu like symptoms including fatigue, nausea, and myalgia. Objective: The purpose of this article is to provide an updated review of the literature in this field. Data Sources: A search of PubMed was performed using the key terms bisphosphonate, acute phase response, and cancer, and limited to publications in English. The published literature on acute phase response with bisphosphonate therapy was reviewed. Results and Conclusions: Approximately 40% of patients receiving aminobisphosphonates experience an acute phase response, which generally occurs only on first exposure to the drug and typically last <72 h. Not all bisphosphonates induce acute phase responses to the same extent. This article reviews acute phase response in patients with metastatic bone disease treated with aminobisphosphonates. J Oncol Pharm Practice (2007) 13: 223—229.Keywords
This publication has 53 references indexed in Scilit:
- Molecular Mechanisms of Action of Bisphosphonates: Current StatusClinical Cancer Research, 2006
- Breast Cancer: Bisphosphonate Therapy for Metastatic Bone DiseaseClinical Cancer Research, 2006
- Recent advances in understanding the mechanism of action of bisphosphonatesCurrent Opinion in Pharmacology, 2006
- Management of the adverse effects associated with intravenous bisphosphonatesAnnals of Oncology, 2006
- Bisphosphonate Treatment Recommendations for OncologistsThe Oncologist, 2005
- Bisphosphonates: Clinical ExperienceThe Oncologist, 2004
- Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing RegimensThe Oncologist, 2004
- C-reactive protein: a critical updateJCI Insight, 2003
- The Systemic Reaction During Inflammation: The Acute-Phase ProteinsProtein & Peptide Letters, 2002
- The acute-phase response after bisphosphonate administrationCalcified Tissue International, 1987